MYELODYSPLASTIC SYNDROME (MDS)
Myelodysplastic syndrome (MDS) is a group of bone marrow disorders characterized by the underproduction of one or more types of blood cells due to a dysfuntion of the marrow. The myelodysplastic syndromes (MDS) may be secondary to treatment with chemotherapy or radiation therapy for another disease.
Patients may exhibit conditions such as low red blood cells (anemia), low white blood cell count (leukopenia) with a tendency to infection, and low platelet count (thrombocytopenia) with bleeding problems. MDS may progress and transform into acute myelogenous leukemia (AML). Chromosome changes involved with MDS include:
• -5/5q- EGR1/D5S721
• -7/7q- CEP7/D7S486
• del(13q14.3) D13S319/LSI13q34
• trisomy 8
• del(20q) D20S108
• 3q26 rearrangement MECOM
FISH analysis can be performed to confirm diagnosis and/or monitor chromosome changes during treatment. Clinicians can order individual probes or the complete MDS panel. Please refer to the Cytogenetics for Hematology/Oncology Disorders test order form to order testing and to review the specimen requirements.
Karyotype analysis can also be performed to confirm the FISH results.
OUHSC Genetics Laboratory 1122 NE 13th Street, Suite 1400, Oklahoma City, OK 73104
Phone (405)271-3589 Fax (405)271-7117 After hours phone (405)496-9514
||Copyright © 2002
The Board of Regents of the University of Oklahoma, All Rights Reserved. OUHSC Home
Disclaimer | Copyright